In 662 BTKi-naive patients with CLL/SLL randomised to pirtobrutinib or ibrutinib, pirtobrutinib was non-inferior for overall response (87.0% vs 78.5%; ratio 1.11), with PFS favouring pirtobrutinib (HR 0.57) and less atrial fibrillation and hypertension.
RCTn = 662
Woyach et al. Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma